Beacon of hope for XLRP patients on Phase III gene therapy success
Phase 3positivelaru-zovaPositive
AI Analysis
Summary
Beacon announced that its VISTA Phase 3 trial of laru-zova met its primary endpoint, marking the first pivotal gene therapy trial for X-linked Retinitis Pigmentosa to achieve this milestone.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
VISTA trial met primary endpoint
Importance:8/10
Sentiment:
0.85
gene therapyXLRPPhase 3clinical trialpositive data
Read the original article
Published by Clinical Trials Arena on September 21, 2026 10:14 AM